Senores Pharmaceuticals Limited (NSE:SENORES)

India · Delayed Price · Currency is INR

1,401.60

-3.50 (-0.25%)

Jul 20, 2026, 12:21 PM IST

127.18% (1Y)

Market Cap	64.71B +127.7%
Revenue (ttm)	6.33B +58.9%
Net Income	1.16B +98.7%
EPS	26.39 +63.9%
Shares Out	46.05M
PE Ratio	53.24
Forward PE	41.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,648
Open	1,395.00
Previous Close	1,405.10
Day's Range	1,382.70 - 1,414.30
52-Week Range	601.10 - 1,509.80
Beta	n/a
Analysts	Strong Buy
Price Target	1,174.25 (-16.22%)
Earnings Date	Jul 24, 2026

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supp... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 2017

Employees 194

Stock Exchange National Stock Exchange of India

Ticker Symbol SENORES

Full Company Profile

Financial Performance

In fiscal year 2026, Senores Pharmaceuticals's revenue was 6.33 billion, an increase of 58.85% compared to the previous year's 3.98 billion. Earnings were 1.16 billion, an increase of 98.74%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for SENORES stock is "Strong Buy." The 12-month stock price target is ₹1,174, which is a decrease of -16.22% from the latest price.

Price Target

₹1,174

(-16.22% downside)

Analyst Consensus: Strong Buy

Stock Forecasts